ArticleBMC cancer2026
Noninvasive preoperative risk stratification of prostate cancer via a foundational model based deep learning with PSMA PET/CT.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo develop and internally validate a PSMA PET/CT–centric deep-learning framework based on using a foundational model for noninvasive preoperative risk stratification of prostate cancer at the ISUP Grade Group (GG) 1–2 vs. 3–5 boundary, without using biopsy-derived inputs at inference.
methodsIn this single-center retrospective cohort, 494 men underwent [18F]PSMA-1007 PET/CT within one month before radical prostatectomy. Intraprostatic ROIs were manually delineated. We developed a dual-path hybrid model that fuses global semantic features from a frozen BiomedCLIP foundation model with task-specific 3D PET/CT features, and used the fused representation for GG 1–2 vs. 3–5 stratification. Five-fold, patient-level cross-validation was used; prostatectomy pathology served as the reference standard. Benchmarks included conventional radiomics and deep-learning baselines (BiomedCLIP-only, ResNet-only, MedSAM, XSurv). The primary metric was AUC; precision, recall, F1, PRC-AUC, and decision-curve analysis (DCA) assessed complementary performance and clinical utility.
resultsThe proposed model achieved AUC 0.800 with precision 0.854, recall 0.888, and F1 0.870, outperforming baselines (BiomedCLIP 0.764; MedSAM 0.759; XSurv 0.756; ResNet 0.745; radiomics/random forest 0.676). Mean PRC-AUC was 0.928 ± 0.020 (across folds), and DCA showed higher net benefit across wide thresholds. SUVmax alone was modest (AUC 0.699 for ≥GG3; 0.625 for ≥GG4).
conclusionThe framework demonstrated noninvasive discrimination of GG 1–2 vs. 3–5 in a single-center cohort, suggesting a candidate decision-support role for biopsy-sparing pathways; its generalizability and deployability require multicenter external validation and end-to-end automation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.